Combination chemotherapy of malignant melanoma with imidazole carboxamide, BCNU and vincristine

Seymour M. Cohen, Ezra M. Greenspan, Lynn H. Ratner, Martin J. Weiner

Research output: Contribution to journalArticlepeer-review

15 Scopus citations

Abstract

Forty patients with disseminated malignant melanoma were treated with triple combination chemotherapy consisting of Imidazole Carboxamide, BCNU and Vincristine. Seventeen of 40 patients (42.5%) showed significant responses including three complete responses. Responses were seen in cutaneous, lymph node and pulmonary metastases. Nine instances of hepatic metastases were unaffected by therapy but 68% of the skin and nodal patients responded. The median response duration was only 4 months and the median survival of responders was 9.5 months compared to a 2 month median survival of nonresponders. Half of the responders died of CNS metastases. The short duration of response, the resistance of hepatic metastasis and the high incidence of cerebral recurrence necessitate additional therapeutic approaches to this disease.

Original languageEnglish
Pages (from-to)41-44
Number of pages4
JournalCancer
Volume39
Issue number1
DOIs
StatePublished - Jan 1977

Fingerprint

Dive into the research topics of 'Combination chemotherapy of malignant melanoma with imidazole carboxamide, BCNU and vincristine'. Together they form a unique fingerprint.

Cite this